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ESOPHAGEAL CANCER 
Dr. Edward Yu 
 
A. Incidence: <5/100,000 in U.S. ; <10/100,000 in Canada. 
gastroesophageal cancer of adenocarcinoma  is  on the rise as compare 
to  squamous cell carcinoma of the esophagus. 
 
B. Risk factors: Tylosis, Plummer-Vinson Syndrome, Caustic Injury,   
    Achalasia, Smoking, Alcohol. 
 
C. Basic patient Work Up requires the following: 
History & Physical 
Barium swallow 
Endoscopy 
CBC, Blood chemistry 








D. Esophageal cancer staging uses TNM system: 
 
Staging (TNM): 
x T1           Tumor invades lamina propria or submucosa. 
x T2                 Tumor invades muscularis propria. 
x T3           Tumor invades adventitia. 
x T4               Tumor invades adjacent structures. 
x N1           Regional nodes mets. 
 
Staging (TNM): 
stage I       T1, N0 
stage II      A- T2-3, N0  ;  B-T1-2,  N1 
stage III    T3-4,  N1 
stage IV     M1  ( including Celiac nodes involvement). 
 
 
E. Esophageal cancer management modality options: 
 
1. Surgery: 
x Aim is to achieve R0 resection (complete resection of tumor). 
x The 5 yr. survival after R0 resection is 15-20%. 
x The median survival is about 18 months. 
 
2. Radiation Therapy: 
x Randomized prospective trial ( Radiation Therapy Oncology Group-
RTOG 8501 ) showed  that radiation alone of 64Gy at 2Gy/fx, 3yr. 
survival  rate  is zero. 
x Radiation therapy alone reserved for palliation or  for medically 
unable to receive chemotherapy. 
x Pre-op. or post-op. radiation therapy has been shown to have   no 
survival benefit. 
x Post-op radiation therapy can offer   local control benefit  in high 
risk patients.( Fok et  al,Surg 1993,Teniere et al., Surg Gyn 1991). 
 
3.  Chemoradiation: 
x Randomized prospective trial (RTOG 8501) also showed that 
combined chemo (5FU/Cisp) + radiation therapy (50Gy) has 
survival benefit  over  radiation therapy (64Gy) alone. 
x The 5 yr. overall survival (OS ) of combined modality is superior   
(27%)  than radiation therapy alone (0%) , median  survival 14 
mos.(month) of combined  versus (VS) 9 mos. of radiation alone. 
x Local failure rate of combined chemoradiation  is   also superior ( 
47% )  over  radiation alone(  65%). 
x Higher dose of radiation  therapy (64.8Gy)  with  same chemo 
showed no additional benefit :  median OS  with   higher radiation 
dose of 13 mos VS  standard 50 Gy of 18.1 mos. not-significance ( 
NS), 2 yr. OS of  31% VS 40%   (NS), and local/regional failure of  
56% VS 52% ( NS). 
x Presently research focus on  new investigational agents : 
paclitaxel- based, docetaxel-based, or irinotecan-based 
chemotherapy to improve overall survival. 
 
 
Randomized Control Trials (RCTs )comparing pre-op chemoradiation 
therapy(Trimodality)  with surgery alone . 
o Although the concept is reasonable,  confirmatory result is still 
pending. 
(Urba et al, JCO 2001; Walsh et al, NEJM 1997; Bosset et al, NEJM 




4.  Brachytherapy: 
xIt is used mainly for palliation when given alone. 
xIt has local control  of 25-35%,  median OS of 5 mos. 
 
RTOG 9207  combined modality(5FU/Cisp/50Gy) followed by intra-luminal  
brachytherapy boost, local failure rate of  27%; acute toxicity Grade 3-5 
58%, 26%, 8% ,respectively; fistula  rate of 18%/yr. ; therefore , at the 
present time brachytherapy is not recommended  by the American 
Brachytherapy Society as a boost when using with high dose rate  
concurrent with chemotherapy. 
 
5.  Chemotherapy: 
x It is used mainly for palliation when given alone. 
x Pre-op chemotherapy may provide small benefit  in survival over 
surgery alone. Confirmative result is pending (Int.0113 study, Thirion et al 
,  Proc ASCO , 2007 ) .  
x Chemotherapy agents for esophageal cancer  include : 
Cisplatinum, most active, >20% response rate.  Others include 5FU, 
Mitomyc. Bleomyc, Doxorub, Vind, Paclit, Vinorel. 
                 5FU + Cisp combination has response  rate of 20-50%. 
 
6. Endoscopic palliation: 
x Laser 
x Ballon dilation 
x Photodynamic 
x Intracavitary irradiation  and   plastic or expandible metal 
prothesis, 
 




MANAGEMENT SUMMARY : 
Trimodality management of resectable esophageal cancer is evolving, many 
cancer centers favour the neoadjuvant  management ( chemoradiation followed 
by surgery) although  final confirmative result is pending.  
 
There is no clinical trial comparing the benefit of  neoadjuvant VS adjuvant 




At  London Regional Cancer Program (LRCP) : 
 
Esophageal cancer that is operable, resectable T1-T3 
 The recommended management is: 
x Esophagectomy 
x  After complete resection: 
o If  N0,   the management is  observation only. 
o If  N1,    (or resection margins involvement) the recommended 
management is post -op      chemoradiation. 
 
Esophageal cancer  that is operable, resectable T1-T3
 It is not unreasonable to offer concurrent chemotherapy (5FU/Cisp) + radiation 
therapy (50Gy)   as an alternative treatment option besides surgery ( RTOG 
8501). Survival can approach that of surgery alone in some circumstances. 
 
Esophageal cancer that is inoperable T4, or  surgery refusal 
 The recommended management is concurrent chemoradiation .     
 
 Inoperable  disease and patient  is unable to tolerate chemotherapy , the 
management can be  best supportive care. 
 
 
  Best supportive care includes the following: 
 
o Obstruction-stent, laser, photodynamic therapy. 
o Radiation therapy (xrt )(external beam, brachytherapy). 
o Nutrition - external feeding( J-tube). 
o Pain control - xrt/medications. 
o Bleeding - xrt/surgery/endoscopic therapy. 
 
 
